Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial

BACKGROUND: Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauz-Körholz, Christine, Landman-Parker, Judith, Balwierz, Walentyna, Ammann, Roland A, Anderson, Richard A, Attarbaschi, Andische, Bartelt, Jörg M, Beishuizen, Auke, Boudjemaa, Sabah, Cepelova, Michaela, Claviez, Alexander, Daw, Stephen, Dieckmann, Karin, Fernández-Teijeiro, Ana, Fosså, Alexander, Gattenlöhner, Stefan, Georgi, Thomas, Hjalgrim, Lisa L, Hraskova, Andrea, Karlén, Jonas, Kluge, Regine, Kurch, Lars, Leblanc, Thiery, Mann, Georg, Montravers, Francoise, Pears, Jean, Pelz, Tanja, Rajić, Vladan, Ramsay, Alan D, Stoevesandt, Dietrich, Uyttebroeck, Anne, Vordermark, Dirk, Körholz, Dieter, Hasenclever, Dirk, Wallace, William Hamish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716340/
https://www.ncbi.nlm.nih.gov/pubmed/34895479
http://dx.doi.org/10.1016/S1470-2045(21)00470-8

Ejemplares similares

Ejemplares similares